Are newer, more expensive pharmacotherapy options associated with superior symptom control compared to less costly agents used in a collaborative practice setting?

American Journal of Hospice and Palliative Medicine

Volumn 23, Issue 2, 2006, Pages 135-149

  Weschules, Douglas J ^a   Maxwell, Terri ^a   Reifsnyder, JoAnne ^a   Knowlton, Calvin H ^a  

^a excelleRx Inc   (United States)

Author keywords

Collaborative practice; Hospice; Pharmaceutical care; Prescribing; Symptom management

Indexed keywords

EID: 33645366160     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910602300211     Document Type: Article

References (72)

1. Resource Kit on Collaborative Practice. Compiled by the 2002 Publications Committee of ACCP, Kansas City: ACCP, 2003.
2. Miaskowski C, Cleary J, Burney R, et al.: Guideline for the Management of Cancer Pain in Adults and Children. APS Clinical Practice Guidelines Series, No. 3. Glen view, IL: American Pain Society, 2005.
3. Coyle N, Adelhardt J, Foley KM, et al.: Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life. J Pain Symptom Manage. 1990; 5(2): 83-93.
4. Gomez-Batiste X, Madrid F, Moreno F, et al.: Breakthrough cancer pain: Prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002; 24(1): 45-52.
5. Gosney M: Cancer in the elderly. In: Sykes N, Fallon M, Patt R (eds): Clinical Pain Management: Cancer Pain. New York: Oxford University Press, 2003.
6. Higgenson IJ, Hearn J, Addington-Hall J: Epidemiology of cancer pain. In: Sykes N, Fallon M, Patt R (eds): Clinical Pain Management: Cancer Pain. New York: Oxford University Press, 2003.
7. Mercadante S, Armata M, Salvaggio L: Pain characteristics of advanced lung cancer patients referred to a palliative care service. Pain. 1994; 59(1): 141-145.
8. Regan J, Peng P: Neurophysiology of cancer pain. Cancer Control. 2000; 7(2): 111-119.
9. Zeppetella G, Riberio MD: Episodic pain in patients with advanced cancer. Am J Hosp Palliat Care. 2002; 19(4): 267-276.
10. Du Pen SL, Du Pen AR, Polissar N, et al.: Implementing guidelines for cancer pain management: Results of a randomized controlled clinical trial. J Clin Oncol. 1999; 17(1): 361-370.
11. Ersek M, Kraybill BM, Du Pen S: Factors hindering patients' use of medications for cancer pain. Cancer Pract. 1999; 7(5): 226-232.
12. Ferrell BR, Juarez G, Borneman T: Use of routine and breakthrough analgesia in homecare. Oncol Nurs Forum. 1999; 26(10): 1655-1661.
13. Miaskowski C, Dodd MJ, West C, et al.: Lack of adherence with the analgesic regimen: A significant barrier to effective cancer pain management. J Clin Oncol. 2001; 19(23): 4273-4274.
14. Muijsers RBR, Wagstaff AJ: Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001; 61(15): 2289-2307.
15. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage. 1997 May; 13(5): 254-261.
16. Wong J-O, Chiu G-L, Tsao C-J, et al.: Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin. 1997; 35(1): 25-32.
17. Hunt R, Fazekas B, Thorne D, et al.: A Comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 1999; 18(2): 111-119.
18. Rischitelli DG, Karbowicz SH: Safety and efficacy of controlled-release oxycodone: A systematic literature review. Pharmacotherapy. 2002; 22(7): 898-904.
19. van Seventer R, Smit JM, Schipper RM, et al.: Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin. 2003; 19(6): 457-469.
20. Weschules DJ, Bain KT, Reifsnyder J, et al.: Toward evidence-based prescribing at end-of-life: A comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl and clinical outcome markers in the hospice patient. Pain Med. 2005 (in press).
21. Clark AJ, Ahmedzai SH, Allan LG, et al.: Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic noncancer pain. Curr Med Res Opin. 2004; 20(9): 1419-1428.
22. Hospice Facts and Figures from the National Hospice and Palliative Care Organization, 2003 data. Available at: www.nhpco.org.
23. Kalso E, Vainio A: Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990; 47: 639-646.
24. Mucci-LoRusso P, Berman BS, Silberstein PT, et al.: Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study. Eur J Pain. 1998; 2: 239-249.
25. Bruera E, Belzile M, Pituskin E, et al.: Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998; 16: 3222-3229.
26. Curtis GB, Johnson GH, Clark P, et al.: Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol. 1999; 55: 435-439.
27. Heiskanen T, Kalso E: Controlled-release oxycodone and morphine in cancer-related pain. Pain. 1997; 73: 37-45.
28. Allan L, Hays H, Jensen N-H, et al.: Randomized crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic noncancer pain. BMJ. 2001; 322: 1154-1158.
29. Guest JF, Ruiz FJ, Russ J, et al.: A comparison of the resources used in advanced cancer care between two different strong opioids: An analysis of naturalistic practice in the UK. Curr Med Res Opin. 2005; 21(2): 271-280.
30. Berger A, Smith M, Lidsky L, et al.: Opioid use and healthcare charges at the end of life in patients with metastatic cancer. Managing Care Interface. 2004; 17(4): 28-34.
31. Roth T: New developments for treating sleep disorders. J Clin Psych. 2001; 62S (10): 3-4.
32. Foley DJ, Monjan AA, Brown SL, et al.: Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep. 1995; 18: 425-432.
33. Savard J, Morin CM: Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol. 2001; 19: 895-908.
34. Couzi RJ, Helzlsouer KJ, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995; 13: 2737-2744.
35. Harrison LB, Zelefsky MJ, Pfister DQ et al.: Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 1997; 19: 169-175.
36. Lindley C, Vasa S, Sawyer WT, et al.: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998; 16: 1380-1387.
37. Holm KJ, Goa KL: Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000; 59(4): 865-889.
38. Nowell PD, Mazumdar S, Buysse DJ, et al.: Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA. 1997; 278(24): 2170-2177.
39. Vermeeren A, O'Hanlon JF, Declerck AC: Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther. 1995; 21(1): 47-64.
40. Fleming J, Moldofsky H, Walsh JK: Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest. 1995; 9(6): 303-313.
41. Rosenberg J, Ahlstrøm F: Randomized, double blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice. Scand J Prim Healthcare. 1994; 12(2): 88-92.
42. Silvestri R, Ferrillo F, Murri L: Rebound insomnia after abrupt discontinuation of hypnotic treatment: Double-blind randomized comparison of zolpidem versus triazolam. Hum Psychopharm. 1996; 11: 225-233.
43. Bain KT, Weschules DJ, Knowlton CH, et al.: Toward evidence-based prescribing at end of life: A comparative review of temazepam and zolpidem for the treatment of insomnia. Am J Hospice Palliat Care. 2003; 20(5): 382-388.
44. Dündar Y, Dodd S, Strobl J, et al.: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: A systematic review and meta-analysis. Hum Psychopharmacol. 2004; 19: 305-322.
45. Oude Voshaar RC, van Balkom AJLM, Zitman FG: Zolpidem is not superior to temazepam with respect to rebound insomnia: A controlled study. Eur Neuropsychopharmacol. 2004; 14: 301-306.
46. Vermeeren A: Residual effects of hypnotics. Epidemiology and clinical implications. CNS Drugs. 2004; 18(5): 297-328.
47. McMillan SC, Small BJ: Symptom distress and quality of life in patients with cancer newly admitted to hospice homecare. One Nurs Forum. 2002; 29(10): 1421-1428.
48. Weitzner MA, Moody LN, McMillan SC: Symptom management issues in hospice care. Am J Hosp Palliat Care. 1997; 14: 190-195.
49. Muir JC, von Gunten CF: Abdominal cancer, nausea, and vomiting. J Palliat Med. 2001; 4(3): 391-394.
50. Gralla RJ, Osoba D, Kris MG, et al.: Recommendations for the use of antiemetics: Evidence-based clinical practice guidelines. J Clin Oncol. 1999; 17(9): 2971-2994.
51. Roberts JT, Priestman TJ: A review of ondansetron in the management of radiotherapy-induced emesis. Oncology. 1993; 50: 173-179.
52. Chen JJ, Frame DG, White TJ: Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures. A randomized, double-blind, comparative trial. Arch Intern Med. 1998; 158: 2124-2128.
53. Chang P, Okamoto M, Chen J, et al.: Cost-effectiveness analysis of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting. J Manag Care Pharm. 2005; 11(4): 317-321.
54. Dresner M, Dean S, Lumb A, et al.: High-dose ondansetron regimen vs. droperidol for morphine patient-controlled analgesia. Br J Anaesth. 1998; 81: 384-386.
55. Mercadante S, Sapio M, Serretta R: Ondansetron in nausea and vomiting induced by spinal morphine. J Pain Sympt Manage. 1998; 16(4): 259-262.
56. Vivian EM: Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002; 22(12): 1533-1540.
57. Borenstein JE, Graber G, Saltiel E, et al.: Physician-pharmacist comanagement of hypertension: A randomized, comparative trial. Pharmacotherapy. 2002; 23(2): 209-216.
58. Coast-Senior EA, Kroner BA, Kelley CL, et al.: Management of patients with Type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998; 32: 636-641.
59. Gattis WA, Hallelblad V, Whellan DJ, et al.: Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Int Med. 1999; 159: 1939-1945.
60. Bogden PE, Koontz LM, Williamson P, et al.: The physician and pharmacist team: An effective approach to cholesterol reduction. J Gen Intern Med. 1997; 12: 158-164.
61. Finley PR, Rens HR, Pont JT, et al.: Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health-Syst Pharm. 2002; 59: 1518-1526.
62. Cannon JP, Silverman RM: A pharmacist-driven antimicrobial approval program at a Veterans Affairs hospital. Am J Health-Syst Pharm. 2003; 60: 1358-1362.
63. Gammaitoni AR, Gallagher RM, Welz M, et al.: Palliative pharmaceutical care: A randomized, prospective study of telephone-based prescription and medication counseling services for treating chronic pain. Pain Med. 2000; 1(4): 317-331.
64. Rapoport A, Akbik H: Pharmacist-managed pain clinic at a Veterans Affairs medical center. Am J Health Syst Pharm. 2004; 61(1): 1341-1343.
65. Gilbert AL, Roughead EE, Beilby J, et al.: Collaborative medication management services: Improving patient care. Med J Aust. 2002; 177: 189-192.
66. Lee AJ, Boro MS, Knapp KK, et al.: Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health-Syst Pharm. 2002; 59: 2070-2077.
67. Leape L, Cullen DJ, Clapp MD, et al.: Pharmacist participation on physician rounds and adverse drug events in the Intensive Care Unit. JAMA. 1999; 282(3): 267-270.
68. Schumock GT, Butler MG, Meek PD, et al.: Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003; 23(1): 113-132.
69. Isetts BJ, Brown LM, Schondelmeyer SW, et al.: Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals. Arch Int Med. 2003; 163: 1813-1820.
70. Hardy J, Daly S, McQuade B, et al.: A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg po with placebo and metoclopramide 10 mg tds po in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002; 10: 231-236.
71. Lindley C, Goodin S, McCune J, et al.: Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: Comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005; 28: 270-276.
72. Currow DC. Coughlan M, Fardell B, et al.: Use of ondansetron in palliative medicine. J Pain Sympt Manage. 1997; 13(5): 302-307.